Publications by authors named "A Adeni"
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC). However, most patients develop acquired drug resistance to EGFR TKIs. HER3 is a unique pseudokinase member of the ERBB family that functions by dimerizing with other ERBB family members (EGFR and HER2) and is frequently overexpressed in -mutant NSCLC.
View Article and Find Full Text PDFPlasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC.
J Immunother Cancer
October 2020
Background: Blood-based biomarkers of anti-solid tumor immune checkpoint blockade (ICB) response are lacking. We hypothesized that changes in systemic cytokine levels with the initial doses of programmed cell death protein 1 (PD-1) pathway inhibitors would correlate with clinical responses. New ultrasensitive ELISA technology enables quantitation of plasma proteins in sub-picogram-per-milliliter concentrations.
View Article and Find Full Text PDFArticle Synopsis
- Pneumothorax and pneumomediastinum are complications that can occur in COVID-19 patients requiring hospitalization, with this study being the largest case series documented to date.
- The research involved a retrospective collection of 71 cases from UK hospitals between March and June 2020, focusing on patients with either pneumothorax, pneumomediastinum, or both.
- Findings indicate that while the survival rates at 28 days were similar for both conditions, older patients (≥70 years) had significantly lower survival rates compared to younger patients.
Small-cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next-generation sequencing (NGS) and by characterizing a representative patient-derived model. We performed targeted NGS, as well as comprehensive pathological evaluation, in 11 never/former light smokers with clinically diagnosed SCLC.
View Article and Find Full Text PDFPurpose: Heterogeneity in tumor mutational burden (TMB) quantification across sequencing platforms limits the application and further study of this potential biomarker of response to immune checkpoint inhibitors (ICI). We hypothesized that harmonization of TMB across platforms would enable integration of distinct clinical datasets to better characterize the association between TMB and ICI response.
Methods: Cohorts of NSCLC patients sequenced by one of three targeted panels or by whole exome sequencing (WES) were compared (total n=7297).